Lived Experiences in early clinical PD: Developing a Framework of a Novel Patient-reported Outcome (PRO) Fit-for-purpose for Disease Modification Therapeutic Trials
Objective: To characterize the lived experience of individuals at a prodromal stage of PD or with a recent clinical diagnosis. Background: There is no validated…Is It Better to Sing Together? A Review of Choral Singing for People with Parkinson’s Disease
Objective: This review assesses the effects of choral singing as an adjunct therapy for Parkinson’s disease (PD). Background: PD is the second-most common neurodegenerative disease,…Interferon Therapy in Subacute Sclerosing Panencephalitis: An Underestimated Option?
Objective: To report the efficacy and safety of long-term intrathecal interferon therapy in a patient with SSPE. Background: Subacute Sclerosing Panencephalitis (SSPE), a fatal progressive…Two Cases of SCN4A Temperature-Sensitive Sodium Channelopathy: From Dystonia to Myotonia
Objective: To evaluate whether these symptoms, previously categorized as dystonic, might represent manifestations of a temperature-sensitive channelopathy with myotonic features [1]. Background: We report two…Artificial Intelligence in the Early Detection of Parkinson’s Disease: Advances, Challenges, and Future Perspectives
Objective: This study reviews AI’s role in early PD detection, comparing AI-driven diagnostic methods with conventional clinical approaches in accuracy, reliability, and applicability. Background: Parkinson’s…Safety, Tolerability, and Preliminary Efficacy of NouvNeu001 for the Treatment of Advanced Parkinson’s Disease: A Multi-center, Open Label, Phase 1 Study
Objective: This Phase 1 study aims to evaluate the safety, tolerability, preliminary efficacy, and optimal dose of NouvNeu001 for treating mid to late-stage Parkinson’s disease…Patient-derived α-synuclein seed amplification as a tool for evaluating small molecule aggregation inhibitors for Parkinson’s disease and Lewy Body Dementia therapeutics
Objective: To validate on-target engagement of disease-relevant ⍺-synuclein (a-syn) aggregates by WTX-607, WaveBreak’s small-molecule clinical candidate for Parkinson’s disease (PD) and Lewy body dementia (LBD),…Diagnostic yield of commercial genetic testing for dystonia in a Canadian movement disorders cohort
Objective: This study aimed to assess the diagnostic yield of commercially available genetic panels in dystonia patients and how test performance varies across dystonia subtypes.…A Novel Quantitative Assessment to Evaluate Functional Impairment in Parkinson’s Disease
Objective: To investigate if motion data collected from inertial measurement units (IMUs) mounted on implements used in activities of daily living (ADLs) can characterize the…Quercetin Reduces mtDNA Release in PRKN-Deficient and Oxidatively Stressed SH-SY5Y Cells
Objective: This study investigates the role of Parkin deficiency in mitochondrial dysfunction and its contribution to mitochondrial DNA (mtDNA) release in Parkinson’s disease (PD). We…
- « Previous Page
- 1
- …
- 99
- 100
- 101
- 102
- 103
- …
- 1734
- Next Page »